Michael Weening Joins Calix as Executive Vice President of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Michael Weening Joins Calix as Executive Vice President of Global Sales

PETALUMA, CA --(Marketwired - June 29, 2016) - Calix, Inc. ( NYSE : CALX ), the world leader in gigabit fiber deployments, today announced that Michael Weening has joined the company as executive vice president of global sales, effective June 27, 2016. A seasoned sales leader, Michael brings a wealth of experience to Calix, having held executive positions in North America, Europe, and Asia.

Michael joins Calix from Salesforce.com, where he was a senior vice president, global customer success and also held the role of senior vice president, Japan and Asia-Pacific customer success, services, and alliances. Previously, he held a number of leadership roles at Bell Mobility in Canada, Microsoft, Dell, and Canon. Michael holds a Bachelor of Arts in Business Administration from Brock University.

About Calix

Calix, Inc. ( NYSE : CALX ) is a global leader in access innovation. Its Unified Access portfolio of broadband communications access software, systems, and services enables communications service providers worldwide to transform their networks and become the broadband provider of choice to their subscribers. For more information, visit the Calix website at www.calix.com .

This press release may contain forward-looking statements that are based upon management's current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this release, and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release, except as required by law. Actual results and the timing of events could differ materially from current expectations based on risks and uncertainties affecting Calix's business. The reader is cautioned not to rely on the forward-looking statements contained in this press release. Additional information on potential factors that could affect Calix's results and other risks and uncertainties are detailed in its quarterly reports on Form 10-Q and Annual Report on Form 10-K filed with the SEC and available at www.sec.gov .

Press Inquiries (Calix): Neila Matheny 707-766-3512 Neila.matheny@calix.com Investor Inquiries (Calix): Thomas J. Dinges, CFA 408-474-0080 tom.dinges@calix.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 250

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 88

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 273

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 241

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
IS: Thai Approval Opens New Sarcoma Treatment Path"> Continue Reading